Stay updated on Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page
- Check4 days agoChange DetectedThe page version/build indicator was updated from v3.5.2 to v3.5.3, reflecting a minor administrative release rather than a substantive change to the trial’s study details.SummaryDifference0.0%

- Check11 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check39 days agoChange Detected- Updated page revision from v3.4.3 to v3.5.0. This appears to be an administrative update and does not modify study details or eligibility criteria.SummaryDifference0.0%

- Check54 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3 as part of a site update. This change does not modify study information or how users interact with the page.SummaryDifference0.0%

- Check75 days agoChange DetectedRevision: v3.4.2 replaces v3.4.1 as a minor metadata update with no changes to study content or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check82 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Brentuximab Post-SCT in Hodgkin Lymphoma Clinical Trial page.